While luminal A breast cancers can largely be treated with endocrine therapies using selective estrogen receptor modulators (SERMs) or aromatase inhibitors which block local estrogen production, approximately 40% of patients either do not respond to these therapies or develop resistance over time [31,32]. Here, ESR1 is linked to breast carcinoma.